Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AlloVir Gains PRIME Status For Anti-Virus T-Cell Therapy

Led By Ex-Alexion CEO David Hallal

Executive Summary

Joining the ElevateBio stable last May, the company has now gained priority status in the US and Europe for its novel therapy for viral infections in stem cell transplant patients.

You may also be interested in...



BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone

Hudson finds solution for legacy sites which have dogged predecessors.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141659

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel